JP2019528260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528260A5 JP2019528260A5 JP2019505515A JP2019505515A JP2019528260A5 JP 2019528260 A5 JP2019528260 A5 JP 2019528260A5 JP 2019505515 A JP2019505515 A JP 2019505515A JP 2019505515 A JP2019505515 A JP 2019505515A JP 2019528260 A5 JP2019528260 A5 JP 2019528260A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- myelodysplastic syndrome
- absence
- mutant allele
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108700028369 Alleles Proteins 0.000 claims description 106
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 86
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 229940125904 compound 1 Drugs 0.000 claims description 26
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 24
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 24
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 21
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims description 21
- 102100030708 GTPase KRas Human genes 0.000 claims description 18
- 101000654718 Homo sapiens SET-binding protein Proteins 0.000 claims description 17
- 101000808799 Homo sapiens Splicing factor U2AF 35 kDa subunit Proteins 0.000 claims description 17
- 102100032741 SET-binding protein Human genes 0.000 claims description 17
- 102100038501 Splicing factor U2AF 35 kDa subunit Human genes 0.000 claims description 17
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 14
- 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 claims description 13
- 101000587430 Homo sapiens Serine/arginine-rich splicing factor 2 Proteins 0.000 claims description 13
- 102100029799 Polycomb group protein ASXL1 Human genes 0.000 claims description 13
- 102100029666 Serine/arginine-rich splicing factor 2 Human genes 0.000 claims description 13
- 102100035595 Cohesin subunit SA-2 Human genes 0.000 claims description 11
- 102100039788 GTPase NRas Human genes 0.000 claims description 11
- 101000642968 Homo sapiens Cohesin subunit SA-2 Proteins 0.000 claims description 11
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 11
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 11
- 101000596772 Homo sapiens Transcription factor 7-like 1 Proteins 0.000 claims description 11
- 101000666382 Homo sapiens Transcription factor E2-alpha Proteins 0.000 claims description 11
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 11
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 11
- 102100038313 Transcription factor E2-alpha Human genes 0.000 claims description 11
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 11
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 claims description 3
- 102100034196 Thrombopoietin receptor Human genes 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 108010076010 Cystathionine beta-lyase Proteins 0.000 claims description 2
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 claims description 2
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 claims description 2
- 102100035813 E3 ubiquitin-protein ligase CBL Human genes 0.000 claims description 2
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 claims description 2
- 101000746364 Homo sapiens Granulocyte colony-stimulating factor receptor Proteins 0.000 claims description 2
- 101000824415 Homo sapiens Protocadherin Fat 3 Proteins 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 102100022134 Protocadherin Fat 3 Human genes 0.000 claims description 2
- 208000034442 Refractory anemia with excess blasts type 1 Diseases 0.000 claims description 2
- 208000034432 Refractory anemia with excess blasts type 2 Diseases 0.000 claims description 2
- 210000003969 blast cell Anatomy 0.000 claims description 2
- 208000012846 myelodysplastic syndrome with excess blasts-1 Diseases 0.000 claims description 2
- 208000012847 myelodysplastic syndrome with excess blasts-2 Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 70
- 230000000392 somatic effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 description 69
- 239000000126 substance Substances 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370373P | 2016-08-03 | 2016-08-03 | |
| US62/370,373 | 2016-08-03 | ||
| US201662429649P | 2016-12-02 | 2016-12-02 | |
| US62/429,649 | 2016-12-02 | ||
| PCT/US2017/045055 WO2018026894A1 (en) | 2016-08-03 | 2017-08-02 | Methods of treatment of myelodysplastic syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528260A JP2019528260A (ja) | 2019-10-10 |
| JP2019528260A5 true JP2019528260A5 (enExample) | 2020-09-17 |
| JP7093764B2 JP7093764B2 (ja) | 2022-06-30 |
Family
ID=68169055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505515A Active JP7093764B2 (ja) | 2016-08-03 | 2017-08-02 | 骨髄異形成症候群の治療方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7093764B2 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012271386A1 (en) | 2011-06-17 | 2014-01-16 | Dana-Farber Cancer Institute, Inc. | Mutation signatures for predicting the survivability of Myelodysplastic Syndrome subjects |
| US11015223B2 (en) | 2013-05-10 | 2021-05-25 | The Regents Of The University Of California | Methods for determining response to a hypomethylating agent |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| ES2989276T3 (es) | 2014-12-05 | 2024-11-25 | Found Medicine Inc | Análisis multigénico de muestras tumorales |
| KR102628370B1 (ko) | 2015-02-04 | 2024-01-24 | 르 라보레또레 쎄르비에르 | 치료적 활성 화합물 및 이들의 사용 방법 |
-
2017
- 2017-08-02 JP JP2019505515A patent/JP7093764B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11976334B2 (en) | Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease | |
| EP2488178B1 (en) | Combinations of a pi3k inhibitor and a mek inhibitor | |
| TW202313041A (zh) | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 | |
| CN102908347A (zh) | 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途 | |
| JP2017537126A5 (enExample) | ||
| EA037152B1 (ru) | Способ лечения рака | |
| JP2018526376A5 (enExample) | ||
| CN1292694A (zh) | 新用途 | |
| TWI751456B (zh) | 癌症療法 | |
| EP3697767A1 (en) | Compounds and methods for treating cancer | |
| JP2005538974A5 (enExample) | ||
| JP2021522246A (ja) | 癌治療のための併用 | |
| JP2022535406A (ja) | Ｐｒｍｔ５阻害剤を使用した癌の治療法 | |
| WO2013022257A2 (ko) | 피라지노-트리아진 유도체를 포함하는 비소세포성폐암 예방 및 치료용 조성물 | |
| JP2021503448A5 (enExample) | ||
| CN112584834B (zh) | 用于治疗结外nk/t细胞淋巴瘤的喹啉衍生物 | |
| JP2019528260A5 (enExample) | ||
| JPWO2022132652A5 (enExample) | ||
| US20210121460A1 (en) | A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor | |
| CN115734968A (zh) | 化合物的盐以及包含盐的药物组合物 | |
| WO2021102004A1 (en) | Dosing regimens for a protein kinase c inhibitor | |
| WO2025162446A1 (zh) | 一种egfr抑制剂的用途 | |
| CN106999485A (zh) | 抗肺鳞癌的喹啉衍生物 | |
| WO2019223672A1 (zh) | 用于治疗非小细胞肺癌的喹啉衍生物 | |
| EP4069243A1 (en) | Combination therapy |